FindTrial
Sign In

Validation and clinical applicability PeriFlux System 5000

Validation and clinical applicability PeriFlux System 5000 - Validation and clinical applicability PeriFlux System 5000

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON30488
Enrollment
10
Registered
2007-06-12
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

arterial occlusive disease atherosclerosis

Interventions

None listed

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: PAOD Fontaine II of the iliacofemoral vessels that will be treated with TEA

Exclusion criteria

Exclusion criteria: Extensive PAOD Fontaine II of other (more distal) vessels Bypass surgery

Design outcomes

Primary

MeasureTime frame
Primairy endpoints of this study are differences in microcirculatory parameters between the Doppler and TcPO2 measurements. In addition, the time needed to perform the measurements will be used as a indicator for the burden for the subject. Total time needed for measurements and analysis will be used as an indicator for clinical applicability.—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)